CL2008000959A1 - Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c. - Google Patents

Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.

Info

Publication number
CL2008000959A1
CL2008000959A1 CL2008000959A CL2008000959A CL2008000959A1 CL 2008000959 A1 CL2008000959 A1 CL 2008000959A1 CL 2008000959 A CL2008000959 A CL 2008000959A CL 2008000959 A CL2008000959 A CL 2008000959A CL 2008000959 A1 CL2008000959 A1 CL 2008000959A1
Authority
CL
Chile
Prior art keywords
thiadiazine
hepatitis
virus
thiazine
prevention
Prior art date
Application number
CL2008000959A
Other languages
English (en)
Inventor
S Dragovich Peter
Viet Tran Chinh
Ruebsam Frank
Zhou Yuefen
E Murphy Douglas
Chen Lijiang
Kucera David
V Martin
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831340&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000959(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of CL2008000959A1 publication Critical patent/CL2008000959A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Compuestos derivados de tiadiazina; composición farmacéutica que los comprende; y su uso para tratar infecciones por el virus de la hepatitis C.
CL2008000959A 2007-04-03 2008-04-02 Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c. CL2008000959A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90747807P 2007-04-03 2007-04-03

Publications (1)

Publication Number Publication Date
CL2008000959A1 true CL2008000959A1 (es) 2008-11-03

Family

ID=39831340

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008000959A CL2008000959A1 (es) 2007-04-03 2008-04-02 Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.

Country Status (23)

Country Link
US (6) US7939524B2 (es)
EP (1) EP2129224B1 (es)
JP (2) JP5739662B2 (es)
KR (1) KR101542516B1 (es)
CN (2) CN104086540B (es)
AR (1) AR065927A1 (es)
AU (1) AU2008237364B2 (es)
BR (1) BRPI0809685A2 (es)
CA (1) CA2682584C (es)
CL (1) CL2008000959A1 (es)
EA (1) EA017685B1 (es)
ES (1) ES2578302T3 (es)
HK (2) HK1137119A1 (es)
IL (2) IL201312A (es)
MX (1) MX2009010564A (es)
MY (1) MY157961A (es)
NZ (1) NZ580445A (es)
PE (1) PE20090220A1 (es)
TN (1) TN2009000398A1 (es)
TW (2) TWI427079B (es)
UA (1) UA100120C2 (es)
WO (1) WO2008124450A1 (es)
ZA (1) ZA200907673B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501039B (zh) 2006-06-22 2012-02-22 安那迪斯药品股份有限公司 吡咯并[1,2-b]哒嗪酮化合物
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
US8097613B2 (en) * 2008-06-10 2012-01-17 Anadys Pharmaceuticals, Inc. [1,2,4]thiadiazine 1,1-dioxide compounds
EP2346329B1 (en) * 2008-10-09 2013-08-21 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
TW201026675A (en) * 2008-10-09 2010-07-16 Anadys Pharmaceuticals Inc 5,6-dihydro-1H-pyridin-2-one compounds
RU2012121847A (ru) * 2009-10-28 2013-12-10 Анадис Фармасьютикалз, Инк. Дейтерированные соединения 5, 6-дигидро-1н-пиридин-2-она
US20130029904A1 (en) 2009-12-18 2013-01-31 Boehringer Ingelheim International Gmbh Hcv combination therapy
US20120321590A1 (en) 2011-04-06 2012-12-20 Anadys Pharmaceuticals, Inc. Bridged polycyclic compounds
WO2012170536A1 (en) * 2011-06-07 2012-12-13 Anadys Pharmaceuticals, Inc. [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
BR112014030623A2 (pt) * 2012-06-12 2017-06-27 Hoffmann La Roche composição, combinação e respectivos usos
EP2943468B1 (en) * 2013-01-14 2017-03-01 F. Hoffmann-La Roche AG A novel process for the preparation of n-(4-nitro-2-sulfamoyl-phenyl)-malonamic acid methyl ester and n-(4-amino-2-sulfamoyl-phenyl)-malonamic acid methyl ester
KR102338461B1 (ko) * 2013-11-13 2021-12-13 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제 억제제의 제조 방법
WO2016130043A1 (ru) * 2015-02-13 2016-08-18 Александ Васильевич ИВАЩЕНКО Бензо[1,2,4]тиадиазиновые ингибиторы репликации вируса гепатита в и фармацевтическая композиция для лечения гепатита в
CN109476699B (zh) 2016-06-02 2021-10-12 艾伯维公司 糖皮质激素受体激动剂及其免疫偶联物
KR20200095477A (ko) 2017-12-01 2020-08-10 애브비 인코포레이티드 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
CN113292574B (zh) * 2020-02-21 2022-05-03 四川大学 一类手性多环的托品烷化合物及其制备方法和用途
JP7435515B2 (ja) * 2021-03-17 2024-02-21 株式会社村田製作所 部品収容装置

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171361A (en) * 1977-03-31 1979-10-16 Eli Lilly And Company 1-Substituted-3-amino-6,7-dialkoxy-1H-1,2,4-benzothiadiazine-1-oxides
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AU2002365198A1 (en) 2001-10-30 2003-07-30 Smithkline Beecham Corporation Novel anti-infectives
KR20050065670A (ko) 2002-11-01 2005-06-29 아보트 러보러터리즈 항감염제
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
DE60335564D1 (de) * 2002-11-01 2011-02-10 Abbott Lab Antiinfektiöse mittel
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
EP1735286B1 (en) * 2004-03-24 2012-01-04 Janssen Pharmaceutica NV Tetrahydro-indazole cannabinoid modulators
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
ATE437875T1 (de) * 2004-08-23 2009-08-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
AU2005316396A1 (en) * 2004-12-17 2006-06-22 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
WO2006093801A1 (en) * 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
JPWO2006115221A1 (ja) 2005-04-21 2008-12-18 日本新薬株式会社 フタラジノン誘導体及びその医薬
AU2006243245A1 (en) * 2005-05-04 2006-11-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2008051637A2 (en) 2006-06-22 2008-05-02 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
CN101501039B (zh) * 2006-06-22 2012-02-22 安那迪斯药品股份有限公司 吡咯并[1,2-b]哒嗪酮化合物
US20080214529A1 (en) 2006-12-12 2008-09-04 Frank Ruebsam SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS
CL2007003587A1 (es) 2006-12-12 2008-07-04 Anadys Pharmaceuticals Inc Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
US20080188466A1 (en) 2006-12-21 2008-08-07 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
US20080275032A1 (en) 2006-12-29 2008-11-06 Yuefen Zhou Pyridazinone compounds
US20080227774A1 (en) 2007-03-15 2008-09-18 Frank Ruebsam 5,5-disubstituted-indolizinone compounds
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
US7834009B2 (en) * 2007-08-27 2010-11-16 Anadys Pharmaceuticals, Inc. 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds

Also Published As

Publication number Publication date
JP5739662B2 (ja) 2015-06-24
US20110166344A1 (en) 2011-07-07
TW200906829A (en) 2009-02-16
EP2129224A1 (en) 2009-12-09
EP2129224A4 (en) 2011-01-05
KR101542516B1 (ko) 2015-08-06
US7939524B2 (en) 2011-05-10
HK1201822A1 (en) 2015-09-11
US9156832B2 (en) 2015-10-13
TWI481588B (zh) 2015-04-21
EA200970916A1 (ru) 2010-04-30
US20150065492A1 (en) 2015-03-05
HK1137119A1 (zh) 2010-07-23
US8765741B2 (en) 2014-07-01
IL225694A0 (en) 2013-06-27
CA2682584C (en) 2017-03-14
ES2578302T3 (es) 2016-07-22
CN101677563B (zh) 2014-06-25
AU2008237364A1 (en) 2008-10-16
TWI427079B (zh) 2014-02-21
BRPI0809685A2 (pt) 2016-09-27
CA2682584A1 (en) 2008-10-16
IL201312A0 (en) 2010-05-31
JP2010523586A (ja) 2010-07-15
MY157961A (en) 2016-08-30
IL225694A (en) 2016-08-31
US20120130068A1 (en) 2012-05-24
EA017685B1 (ru) 2013-02-28
CN101677563A (zh) 2010-03-24
JP2015134783A (ja) 2015-07-27
ZA200907673B (en) 2014-04-30
US20120302744A1 (en) 2012-11-29
WO2008124450A1 (en) 2008-10-16
AR065927A1 (es) 2009-07-08
TN2009000398A1 (en) 2010-12-31
UA100120C2 (en) 2012-11-26
US20100034773A1 (en) 2010-02-11
CN104086540A (zh) 2014-10-08
IL201312A (en) 2015-05-31
PE20090220A1 (es) 2009-03-12
KR20090127437A (ko) 2009-12-11
AU2008237364B2 (en) 2014-03-06
JP5934403B2 (ja) 2016-06-15
NZ580445A (en) 2012-01-12
US8546602B2 (en) 2013-10-01
EP2129224B1 (en) 2016-03-30
US8236948B2 (en) 2012-08-07
CN104086540B (zh) 2017-04-12
MX2009010564A (es) 2009-10-26
US8101800B2 (en) 2012-01-24
US20140031346A1 (en) 2014-01-30
TW201431830A (zh) 2014-08-16

Similar Documents

Publication Publication Date Title
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
UY29266A1 (es) Compuestos de piridazinona
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
ECSP055801A (es) Compuestos benzofuránicos, composiciones y métodos para el tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas
HN2012001162A (es) Triazolopiridinas
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
BRPI0606524A2 (pt) derivados de indol para o tratamento de infecções virais
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
GT200600327A (es) Ciclohexilaminoisoquinolona
BRPI0619153B8 (pt) derivados de 4-amino-pirroltriazina substituída, e composição farmacêutica
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0607017B8 (pt) composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
CL2008000946A1 (es) Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
UY30778A1 (es) Compuestos de 5,6-dihidro-1h-piridin-2-ona
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
PE20191652A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
BR0308653A (pt) Cristais de derivado de benzeno de glicopiranosiloxibenzila